NEUEXCELL

Serial Number 98432310
748

Registration Progress

Application Filed
Mar 4, 2024
Under Examination
Dec 24, 2024
Approved for Publication
Nov 12, 2024
Published for Opposition
Nov 12, 2024
Registered

Trademark Image

NEUEXCELL

Basic Information

Serial Number
98432310
Filing Date
March 4, 2024
Published for Opposition
November 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
748
Status Date
Nov 25, 2025
Application
Pending
Classes
042

Rights Holder

NeuExcell Therapeutics Inc.

03
Address
401 N. Broad St., Suite 242
Philadelphia, PA 19108

Ownership History

NeuExcell Therapeutics Inc.

Original Applicant
03
Philadelphia, PA

NeuExcell Therapeutics Inc.

Owner at Publication
03
Philadelphia, PA

Legal Representation

Attorney
Lawrence M. Green

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

12 events
Date Code Type Description Documents
Nov 25, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jun 5, 2025 IUAF S USE AMENDMENT FILED Loading...
Nov 25, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 5, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 24, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 12, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 12, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 23, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 1, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 18, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 15, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 4, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Research and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment
First Use Anywhere: Mar 31, 2025
First Use in Commerce: Mar 31, 2025

Classification

International Classes
042